Revolution Medicines, Inc (RVMD)

Etorro trading 970x250
Revolution Medicines, Inc (RVMD) Logo

About Revolution Medicines, Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California. Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063

Revolution Medicines, Inc News and around…

Latest news about Revolution Medicines, Inc (RVMD) common stock and company :

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
24 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside ch

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
10 Nov, 2021 Yahoo! Finance

RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company Poised to Select Additional RAS(ON) Development Candidate in 2021; Mutant-Selective Inhibitors of KRASG13C and KRASG12D Showing Preclinical Promise Global Phase 2 Study, RMC-4630-03, Recruiting Patients to Evaluate RMC-4630 in Combination with Lumakras™ REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a firesi

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline
04 Nov, 2021 Yahoo! Finance

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
03 Nov, 2021 Yahoo! Finance

Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern TimeREDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that it will report financial results for the third quarter 2021 on November 10, 2021 after market close. The company will host a confe

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
27 Oct, 2021 Yahoo! Finance

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

Hedge Funds Are Crazy About Revolution Medicines, Inc. (RVMD)
18 Oct, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

It's a Done Deal: 365 Cannabis Sold to Akerna
11 Oct, 2021 FinancialContent

Viridian Capital Advisors, a leading financial advisory firm in the legal cannabis industry, today announced the sale of its ...

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
15 Sep, 2021 FinancialContent

Company’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

77 Biggest Movers From Yesterday
13 Aug, 2021 FinancialContent

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company ...

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
13 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

12 Health Care Stocks Moving In Thursday's Intraday Session
12 Aug, 2021 FinancialContent

Gainers NanoVibronix (NASDAQ:NAOV) stock increased by 23.8% to $2.86 during Thursday's regular session. As of 12:30 ...

54 Stocks Moving In Thursday's Mid-Day Session
12 Aug, 2021 FinancialContent

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 64.2% to $2.0850 after the company announced it is expanding its ...

Revolution Medicines Enters Oversold Territory (RVMD)
12 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Stocks That Hit 52-Week Lows On Thursday
12 Aug, 2021 FinancialContent

During Thursday's morning trading, 83 companies set new 52-week lows. Intriguing Points: KE Holdings ...

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
12 Aug, 2021 FinancialContent

Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd (NASDAQ:PCOM) was changed ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates
11 Aug, 2021 Yahoo! Finance

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines: Q2 Earnings Insights
11 Aug, 2021 FinancialContent

Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
11 Aug, 2021 FinancialContent

Gainers Hims & Hers Health (NYSE:HIMS) shares moved upwards by 12.53% to $8.44 during Wednesday's after-market session. This ...

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
11 Aug, 2021 FinancialContent
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For August 11, 2021
11 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
04 Aug, 2021 FinancialContent

Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline
02 Aug, 2021 Yahoo! Finance

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revolution Medicines, Inc (RVMD) is a NASDAQ Common Stock listed in , ,

970x250